This reveals that GSDMD affects VSMC activity through a novel mechanism that is independent of pyroptosis, as GSDMD siRNA does not alter LDH release.439 They suggest that targeting GSDMD and putrescine may represent a novel therapeutic avenue for the treatment of AAA. Here, GSDMD is linked to triple-A syndrome.